Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Peripheral NeuropathyNeuropathic Pain
Interventions
DRUG

ADL5859

DRUG

Duloxetine

DRUG

Placebo

Trial Locations (27)

16602

Advanced Regional Center for Clinical Research (Ankle & Foot Care), Altoona

16635

Altoona Center for Clinical Research, Duncansville

23451

Tidewater Integrated Medical Research, Virginia Beach

28801

Clnical Study Center of Asheville, Asheville

32446

Panhandle Family Care Associates & Emerald Coast Research Grp, Inc., Marianna

33143

Doctor's Research Network, South Miami

33401

Metabolic Research Institute, Inc., West Palm Beach

33407

Laszlo J. Mate, MD, West Palm Beach

33770

Innovative Research of West Florida, Inc., Largo

33781

Radiant Research-St.Petersburg, Pinellas Park

34471

Renstar Medical Research, Ocala

34741

FPA Clinical Research, Kissimmee

40503

The Pain Treatment Center of the Bluegrass, Lexington

43623

Neurology & Neuroscience Center of Ohio, Toledo

44260

Radiant Research-Akron, Mogadore

63031

Healthcare Research, Florissant

68131

Creighton Diabetes Center, Creighton Univ. Sch. of Medicine, Omaha

73099

Aquilo Research, Yukon

77030

Nerve & Muscle Center of Texas, Houston

78217

Invisions Consultants LLC, San Antonio

78229

Diabetes & Glandular Disease Research Associates, San Antonio

S.A.M. Clinical Research Center, San Antonio

89123

Advanced Biomedical Research of America, Las Vegas

90505

Torrance Clinical Research, Torrance

92506

Integrated Research Group, Riverside

97504

Clinical Research Consultants, Research Department, Medford

02301

Beacon Clinical Research, Brockton

All Listed Sponsors
lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00603265 - Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy | Biotech Hunter | Biotech Hunter